ARENSIA BEGINS CLINICAL TRIAL PROGRAM TO TEST DIFFUSION’S LEAD DRUG FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

We at ARENSIA are proud to announce today that we have entered into an agreement with Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to begin a clinical trial program to test Diffusion’s lead drug trans sodium crocetinate (TSC) for the treatment of hospitalized COVID-19 patients presenting with lowered blood oxygen levels, a condition known as hypoxemia.

The trial will be performed at the National Institute of Infectious Diseases “Prof. Dr. Matei Bals” (NIID) in Bucharest, Romania, where ARENSIA conducts the most complex exploratory clinical trials on a wide range of infectious diseases in advanced specialist Phase I facilities. Noted infectious disease researcher Prof. Adrian Streinu-Cercel, M.D., Ph.D., General Manager of the NIID, will serve as Principal Investigator.

We will valiantly overcome any obstacles in the way of this program, as this is our contribution to overcoming the pandemic and saving countless human lives!

Below, please find Diffusion Pharmaceutical’s press release:

https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases/default.aspx

21.05.2020